Switzerland Archives

adc therapeutics genomics sophia genetics blood cancer

News and Trends 6 Aug 2019

ADC Therapeutics and SOPHiA Genetics Team Up to Personalize Cancer Treatment

Two companies based in Lausanne, Switzerland — ADC Therapeutics and the genomics company SOPHiA Genetics — have signed a deal to identify patients most likely to respond to a blood cancer drug. ADC Therapeutics will send SOPHiA Genetics blood samples collected from an ongoing phase II trial. The trial is testing a treatment for patients […]

August 6, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 31 Jul 2019

Wellington Partners Raises €210M to Invest in European Life Sciences

VC firm Wellington Partners has raised its fifth fund dedicated to investing in life science companies, with a major focus on those located in German-speaking countries. Wellington Partners has well surpassed its initial target of €150M for its fifth life sciences fund. With a total €210M raised, this new fund is more than double the […]

July 31, 2019 - 3 minutesmins - By Clara Rodríguez Fernández

Catherine Pickering iOnctura e1575382680993

Interview 22 Jul 2019

Turning Shelved Drugs into a New Promise for Immuno-Oncology

After working for 12 years at Merck, Catherine Pickering decided to take a risk and create iOnctura, a spin-out company exploring a new application in immuno-oncology for a drug candidate that had been shelved. In the last decade, there has been a massive boom in the development of cancer therapies that use and enhance the […]

July 22, 2019 - 5 minutesmins - By Clara Rodríguez Fernández

pneumonia polyphor antibiotic murepravadin

More News! 18 Jul 2019

Swiss Pneumonia Antibiotic Abandoned in Phase III

The Swiss biotech Polyphor has discontinued two phase III trials of its antibiotic for treating pneumonia after halting both trials due to safety concerns in May. The two phase III trials were testing Polyphor’s intravenous antibiotic murepavadin in hospitalized patients with pneumonia. In May, Polyphor halted the two trials due to an unexpectedly high incidence […]

July 18, 2019 - 2 minutesmins - By Jonathan Smith

boehringer ingelheim cancer vaccine amal therapeutics

News and Trends 16 Jul 2019

Boehringer Ingelheim Acquires Cancer Vaccine Biotech in €325M Deal

The German giant Boehringer Ingelheim has acquired the Swiss company AMAL Therapeutics and its cancer vaccine technology in a deal worth up to €325M. The deal includes €225M in upfront and developmental milestone payments, as well as up to €100M in undisclosed commercial milestone payments. AMAL’s vaccine development pipeline includes five preclinical programs. The lead […]

July 16, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 17 Jun 2019

Swiss Anti-Aging Treatment Gives the Elderly Healthier Muscles

An anti-aging dietary supplement developed by the Swiss biotech Amazentis to combat age-related muscle weakening has improved the health of muscle cells in a first-in-human study. Mitochondria are parts of the cell that generate energy, and are important for muscle movement. As we age, damaged mitochondria begin to build up in muscle cells, possibly contributing […]

June 17, 2019 - 2 minutesmins - By Jonathan Smith

Interview 30 May 2019

Taking Inspiration from Plants to Prevent Mold from Ruining Crops

Olga Dubey founded the Swiss startup Agrosustain with the intention to bring forth a natural alternative to chemical pesticides against mold. She shares how it all started and her company’s plans to end the massive amounts of food waste that mold is responsible for. “Mold is everywhere, so it’s something that is very hard to […]

May 30, 2019 - 4 minutesmins - By Clara Rodríguez Fernández

Molecular Partners drug development cancer

Interview 16 May 2019

Taking a Drug to Market “Is a Marathon, Not a Sprint”

Based in Zurich, Molecular Partners is developing a new class of drugs that can address the complexity of cancer. At Labiotech Refresh in Zurich, CEO Patrick Amstutz shared what he’s learned on the journey to take the company where it is today. After completing a PhD at ETH Zurich, Amstutz founded Molecular Partners with a […]

May 16, 2019 - 4 minutesmins - By Clara Rodríguez Fernández

News and Trends 13 May 2019

‘Guided Missile’ Cancer Immunotherapy Boosted by €62M Funding

The Swiss-Italian biotech company Philogen has raised a private round of €62M to fund the phase III development of cancer immunotherapies that deliver immune cell-stimulating molecules directly to the tumor site. The money will push Philogen’s two lead cancer programs, currently in phase III, to the market. The funds will also help to expand the […]

May 13, 2019 - 2 minutesmins - By Jonathan Smith

pneumonia lungs polyphor antibiotic resistance

News and Trends 10 May 2019

Swiss Biotech Halts Pneumonia Antibiotic Trial After Patient Safety Scare

Polyphor has temporarily halted two phase III trials of an antibiotic treating pneumonia, after an unexpectedly high number of patients reported kidney problems in one of the trials. The phase III trial was testing the antibiotic murepavadin in 150 enrolled patients with hospital-acquired pneumonia, and who required mechanical breathing. The patients in the treatment group […]

May 10, 2019 - 3 minutesmins - By Jonathan Smith

achondroplasia pfizer therachon acquisition

More News! 9 May 2019

Pfizer Pays up to €700M to Acquire Swiss Biotech Restoring Bone Growth in Achondroplasia

Pharma giant Pfizer is acquiring the Swiss biotech Therachon, which is developing a protein drug to boost bone growth in the genetic condition achondroplasia. Pfizer will pay €303M ($340M) upfront, and up to €420M ($470M) dependent on Therachon reaching milestones in the development of its drug improving bone growth in achondroplasia. This genetic condition inhibits […]

May 9, 2019 - 2 minutesmins - By Jonathan Smith

Best in Biotech 8 May 2019

Top 10 Biotechs in Lausanne

The Swiss city of Lausanne is perhaps best known as a hub of international sport, but what many outsiders may not realize is that it’s also one of Switzerland’s biggest biotech hubs. Many of the biotechs in the city are connected to the University of Lausanne (UNIL), as well as the renowned Swiss Federal Institute […]

May 8, 2019 - 7 minutesmins - By David Cox

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Switzerland

ADC Therapeutics and SOPHiA Genetics Team Up to Personalize Cancer Treatment

Wellington Partners Raises €210M to Invest in European Life Sciences

Turning Shelved Drugs into a New Promise for Immuno-Oncology

Swiss Pneumonia Antibiotic Abandoned in Phase III

Boehringer Ingelheim Acquires Cancer Vaccine Biotech in €325M Deal

Swiss Anti-Aging Treatment Gives the Elderly Healthier Muscles

Taking Inspiration from Plants to Prevent Mold from Ruining Crops

Taking a Drug to Market “Is a Marathon, Not a Sprint”

‘Guided Missile’ Cancer Immunotherapy Boosted by €62M Funding

Swiss Biotech Halts Pneumonia Antibiotic Trial After Patient Safety Scare

Pfizer Pays up to €700M to Acquire Swiss Biotech Restoring Bone Growth in Achondroplasia

Top 10 Biotechs in Lausanne

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!